Literature DB >> 11720682

Why perform randomized clinical trials for sentinel node surgery for breast cancer?

D Krag1.   

Abstract

Long-term outcome of sentinel node surgery without axillary dissection has not been established. To that extent the therapeutic outcome of sentinel node surgery is unknown. Two important clinical trials are under way that are designed to compare sentinel node surgery without axillary dissection to axillary dissection. In partnership with the University of Vermont, the National Surgical Adjuvant Breast and Bowel Project is conducting a trial that will primarily compare node negative breast cancer cases. The American College of Surgeons Clinical Oncology Group is conducting a trial that randomizes node positive breast cancer patients. The primary endpoints of these clinical trials are survival, long-term regional control, and morbidity. At the conclusion of these trials it will be established within a narrow confidence interval whether sentinel node surgery alone provides the same important therapeutic benefits as axillary surgery but without the morbidity associated with axillary surgery.

Entities:  

Mesh:

Year:  2001        PMID: 11720682     DOI: 10.1016/s0002-9610(01)00728-0

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  3 in total

1.  Failure of routine axillary nodal sampling to predict survival outcomes in lymph node-negative (N0) breast cancer.

Authors:  Kirby I Bland
Journal:  Ann Surg       Date:  2003-02       Impact factor: 12.969

2.  Re-evaluation of axillary skip metastases in the era of sentinel lymph node biopsy in breast cancer.

Authors:  Mehmet Keskek; Sener Balas; Aytac Gokoz; Iskender Sayek
Journal:  Surg Today       Date:  2006-12-25       Impact factor: 2.549

Review 3.  Clinical evidence of breast cancer micrometastasis in the era of sentinel node biopsy.

Authors:  Noriaki Wada; Shigeru Imoto
Journal:  Int J Clin Oncol       Date:  2008-02-29       Impact factor: 3.402

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.